Thursday, 26 Apr 2018

You are here

Top 16 Drugs in Rheumatology 2016

Using data compiled from annual reports, SEC filings, press releases, company websites, recently released sales figures show that in 2016, 11 of the top 16 rheumatology drugs demonstrated blockbuster sales (>$1 billion per annum).  Highlights from this report include:

  • TNF inhibitors – the big three TNFi (ADA, ETN, INF) lead the way with $33.7 billion in 2016.  Humira continued as the worldwide leader in sales $16.1 billion.  Sales of all 5 TNFi totaled $37.9 billion.  While Humira growth (15%) continues, Enbrel has flattened (2%) and Remicade has declined (-2%).
  • Greatest growth from 2015 to 2016 was Cosentyx (332% to $1.1 billion in 2016), Otezla (116% to $1 billion) and Xeljanz (77% to $927 million).
  • Greatest losses were seen for NSAID market, with -12% drop for Celebrex, -4% drop for Arcoxia (Cox-2 inhibitor sold outside the USA) and a -2% drop for aspirin.
  • Psoriatic arthritis therapeutic market was hot with substantial growth by Cosentyx (332%), Otezla (116%) and Stelara (31%), in addition to TNF inhibitor growth.

TOP 16 RHEUMATOLOGY DRUGS – 2016 SALES

 

Brand

Generic

2015 Sales*

2016 Sales*

Growth Rate

1

Humira

Adalimumab

14012

16078

15%

2

Enbrel

Etanercept

8697

8874

2%

3

Remicade

Infliximab

8791

8789

-2%

4

Rituxan

Rituximab

5584

5765

3%

5

Stelara

Ustekinumab

2474

3232

31%

6

Simponi

Golimumab

2133

2719

27%

7

Orencia

Abatacept

1957

.2368

21%

8

Actemra

Tocilizumab

1432

1697

19%

9

Cimzia

Certolizumab

1191

1438

21%

10

Cosentyx

Secukinumab

261

1128

332%

11

Otezla

Apremilast

472

1017

116%

12

Xeljanz

Tofacitinib

523

927

77%

13

Celebrex

Celcoxib

830

733

-12%

14

Aspirin

Aspirin

525

513

-2%

15

Arcoxia

Etoricoxib

471

450

-4%

16

Ilaris

Canakinumab

236

283

20%

* Worldwide sales expressed millions (USD)

Add new comment

More Like This

FDA Advisors Weigh COX-2 Inhibitor Safety

Should celecoxib (Celebrex) be officially declared as no riskier for the heart than other non-steroidal anti-inflammatory drugs (NSAIDs) naproxen and ibuprofen, and do those other NSAIDs interfere with aspirin for cardiovascular prevention?

Will Aspirin Cotherapy Undermine Celecoxib’s Safety Effects?

The PRECISION study took 11 years and 24,081 patients (90% OA; 10% RA). It showed that celecoxib had fewer gastrointestinal events, fewer renal events and less ATPC cardiac events compared to ibuprofen - with an 18% reduction in major CV events and a 32% reduction in all-cause mortaility compared to ibuprofen.

Medicare Drug Prices Jump Ten Times the Inflation Rate

CNN reports that a new congressional analysis of Medicare drug pricing shows the prices of the 20 most commonly prescribed brand-name drugs have risen nearly 10 times the annual rate of inflation in the past five years.

Shoe Inserts Disappoint with Plantar Heel Pain

A report from the British Journal of Sports Medicine shows that commonly used drug store shoe inserts or customized orthotics are often ineffective in managing plantar heel pain.

Leflunomide May Sensitize the Insulin Receptor and Have an Anti-Glycemic Effect

An animal model study in the Journal of Endocrinololgy reports the potential use of leflunomide in the control of hyperglycemia in male mice.